Inventor · disambiguated record
David R. Anderson
Also filed as: ANDERSON DAVID R · ANDERSON DAVID RANDOLPH
37 granted patents·14 pending applications·119 citations·filing 2003–2024
97Inventor score
Top patents by PatentIndex Score
51 records- 0197US11702424B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2020·Granted Jul 18, 2023·4 cites·8 claims
- 0296US11236104B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2020·Granted Feb 1, 2022·4 cites·28 claims
- 0396US10981906B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Apr 20, 2021·9 cites·21 claims
- 0495US9879022B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2016·Granted Jan 30, 2018·19 cites·22 claims
- 0594US11739086B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·4 cites·5 claims
- 0694US10800775B2Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the sameACLARIS THERAPEUTICS INC·Filed 2018·Granted Oct 13, 2020·8 cites·20 claims
- 0794US10626122B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 21, 2020·8 cites·16 claims
- 0893US10500205B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Dec 10, 2019·10 cites·22 claims
- 0992US11820775B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2021·Granted Nov 21, 2023·2 cites·34 claims
- 1091US12145909B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BNOVARTIS AG·Filed 2022·Granted Nov 19, 2024·1 cites·21 claims
- 1191US10793579B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2019·Granted Oct 6, 2020·3 cites·8 claims
- 1291US10752633B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Aug 25, 2020·9 cites·5 claims
- 1391US10584131B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Mar 10, 2020·9 cites·2 claims
- 1490US12281111B2Substituted pyrrolopyridine JAK inhibitors and methods of making and using the sameACLARIS THERAPEUTICS INC·Filed 2023·Granted Apr 22, 2025·1 cites·7 claims
- 1590US12161624B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·1 cites·20 claims
- 1690US11807650B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2022·Granted Nov 7, 2023·1 cites·17 claims
- 1790US10973825B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 13, 2021·6 cites·16 claims
- 1887US11541057B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
- 1987US11274107B2NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2017·Granted Mar 15, 2022·3 cites·20 claims
- 2087US9963434B2N-arylmethyl sulfonamide negative modulators of NR2ALUC THERAPEUTICS·Filed 2014·Granted May 8, 2018·8 cites·25 claims
- 2186US11542264B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·2 claims
- 2286US10329302B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2018·Granted Jun 25, 2019·3 cites·2 claims
- 2385US12297203B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2023·Granted May 13, 2025·0 cites·5 claims
- 2485US12202836B2Bicyclic-fused heteroaryl or aryl compoundsPFIZER·Filed 2023·Granted Jan 21, 2025·0 cites·14 claims
- 2582US11021482B2Pyrrolopyrimidine ITK inhibitorsACLARIS THERAPEUTICS INC·Filed 2019·Granted Jun 1, 2021·2 cites·21 claims
- 2682US2025034145A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2781US12358929B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Granted Jul 15, 2025·0 cites·14 claims
- 2881US10781174B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BCADENT THERAPEUTICS INC·Filed 2019·Granted Sep 22, 2020·1 cites·31 claims
- 2980US2024199617A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3076US12162890B2Heteroaromatic NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 3174US11648253B2Thienopyrimidinone NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted May 16, 2023·0 cites·19 claims
- 3271US11116749B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BCADENT THERAPEUTICS INC·Filed 2018·Granted Sep 14, 2021·0 cites·9 claims
- 3371US10239835B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2BLUC THERAPEUTICS INC·Filed 2015·Granted Mar 26, 2019·1 cites·22 claims
- 3470US2020369610A1N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2bCADENT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3566US2022372034A1Substituted pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3664US2005143371A1Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitorsPHARMACIA CORP·Filed 2004·Application pending·0 cites
- 3763US2005137220A1Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitorsPHARMACIA CORP·Filed 2004·Application pending·0 cites
- 3859US2019352300A1Pyrrolopyrimidine itk inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3958US10316038B2Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancerACLARIS THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·27 claims
- 4057US12403141B2Deuterated MK2 pathway inhibitors and methods of using the sameACLARIS THERAPEUTICS INC·Filed 2020·Granted Sep 2, 2025·0 cites·7 claims
- 4157US11420966B2Substituted pyrrolopyridines as JAK inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Granted Aug 23, 2022·0 cites·17 claims
- 4256US9540324B2Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2BMNEMOSYNE PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·0 cites·18 claims
- 4353US10052306B2Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2BLUC THERAPEUTICS INC·Filed 2016·Granted Aug 21, 2018·0 cites·30 claims
- 4453US2004209897A1Mitogen activated protein kinase-activated protein kinase-2 inhibiting compoundsPHARMACIA CORP·Filed 2003·Application pending·0 cites
- 4553US2004127519A1Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitorsPHARMACIA CORP·Filed 2003·Application pending·0 cites
- 4652US2005101623A1Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitorsPHARMACIA CORP·Filed 2004·Application pending·0 cites
- 4751US2022235043A1Substituted sulfonamide pyrrolopyridines as jak inhibitorsACLARIS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4845US6909001B2Method of making tricyclic aminocyanopyridine compoundsPHARMACIA CORP·Filed 2003·Granted Jun 21, 2005·0 cites·17 claims
- 4944US2004142978A1Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2PHARMACIA CORP·Filed 2003·Application pending·0 cites
- 5043US2004127511A1Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2PHARMACIA CORP·Filed 2003·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David R. Anderson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →